Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a substantive review by the FDA.
“This 510(k) submission is a major step towards gaining entry to the U.S. market for Bentrio and we look forward to working closely with the FDA as it proceeds through its review,” Thomas Meyer, founder, chairman and CEO of Altamira, said in a statement.
